Escala Medical

Non-surgical, incision-free approach to treat pelvic organ prolapse

Technology Development

Business Development





Edit Goldberg
Contact Us
email email
Follow Us
The Trendlines Group, the Israel Innovation Authority


Escala has developed the first minimally invasive, incision-free repair solution to Pelvic Organ Prolapse (POP). Their device addresses the need, offering a non-surgical repair alternative that is safe and easy to perform.

The incision-free procedure is performed under mild local anaesthesia and does not require longer than 20 minutes. Shifting prolapse repair from inpatient/outpatient setting to office-based procedures has the potential to change the way POP is treated today. Escala’s device has FDA clearance.

The Escala device is a tissue anchoring, approximation and fixation system intended for anchoring sutures to ligaments of the pelvic floor. The device utilizes an incision-free vaginal approach allowing fixation of the vaginal apex to the sacrospinous ligament (SSL) for apical suspension. Apical suspension is regarded as the most important component in prolapse repair increasing the long-term success of the repair procedure.

This device brings a new treatment alternative to the women suffering from prolapse that currently either wait until their condition deteriorates to a stage requiring surgery or continue to compromise on quality of life.

Market Need

Pelvic Organ Prolapse (POP) is a highly prevalent debilitating condition in women’s health. It affects 1 in 3 women worldwide and occurs when one or more of the organs in the pelvis slip down from their normal position. POP causes pain and discomfort and has a substantial impact on the quality of life and psychological well-being of the sufferer.
Current treatments available for women with POP are insufficient and limited. Supportive devices (pessaries) do not repair and provide only a temporary solution. Surgical repair procedures for prolapse are the most common inpatient procedures for women over 70 years old as half of the women that had given birth will suffer from prolapse during their lifetime.

The lifetime risk of undergoing POP surgery has been estimated at 12.6% with ten-year reoperation rates as high as 17%. The prevalence of POP is similar all over the world.
Women that had failed the supportive treatment, or that are poor surgical candidates or that are reluctant to undergo continue to compromise on their quality of life as appropriate treatment alternative is currently not available.
Currently, no “mid-path” repair solution that does not involve any cuts or the use of mesh is available in the market.

Pelvic Organ Prolapse (POP) is seen on examination in 50% of women that had given birth.

Skip to content